A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. - Wikidata - wikimedia - TriplyDB

A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.

A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.

http://www.wikidata.org/entity/Q39430232

about

Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy Hepatitis C cirrhosis: New perspectives for diagnosis and treatment Burden of disease and cost of chronic hepatitis C infection in Canada Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.HIV, Aging, and Viral Coinfections: Taking the Long View.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus.Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.Personalized management of hepatocellular carcinoma based on molecular information: future prospects.Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis.Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.Hepatitis C virus infection in Argentina: Burden of chronic disease.Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden Influencing factors of transient elastography in detecting liver stiffness.A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment.Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?The evolving epidemiology of hepatocellular carcinoma: a global perspective.

P2860

Q26752433-DBCBAD01-C2B9-4278-9FB1-D2849AF9C131 Q26765476-454D05BC-09A3-4A51-9B98-9DF406695852 Q26766707-1F997770-2D73-4140-A721-A6EABDE7C8F4 Q26795750-2717E99E-9559-4D28-98A3-96988224E214 Q26799924-D3C4826B-C1F1-46E5-B57D-ABC3A9270390 Q26849591-80899B3C-CE01-4837-BE2C-80F4F693F3EA Q28072257-845C4C5A-8B2C-459E-A32C-6FA9F09394F9 Q28075646-5F319182-5F83-4DFD-B563-DC2E8C806FAD Q28548657-5BC1B05E-1A5A-4AA9-BEC7-7C7FD0580A7F Q30244361-E3A1F57D-EE70-483F-BD42-8B7786F7853A Q30245486-DA76D97B-E780-4BF4-9FD8-D3308AFAF954 Q30250096-E94FFAE0-8E3E-44F1-AA16-8CA225463A2C Q30250322-C31181BD-68AB-4EE6-B993-EBEACF257866 Q33731308-0B8A1F0B-8F1B-4E2C-A54B-75B6F30C8DFE Q33807745-DE6D5179-D51D-462F-AD5F-6E2DAB0ADD75 Q34028307-55A4CE39-8562-4A4B-9A75-339BC5A0D277 Q34987336-2E02738F-638B-480F-BC2F-24909C6825BD Q35105799-F97BD592-B117-4C8B-9D62-641C8BB7A504 Q35143996-2B8C6759-5270-4653-9D07-97713753494F Q35715916-9D44D73C-A3ED-421E-AA68-76FAA9966227 Q35881575-FB5780D5-D97E-496F-9390-F7716E7FC6A0 Q35933802-184AAE14-C406-4BE0-8EDF-279D91298DBE Q35985401-3003B867-F412-49FB-BB16-88FAD42F53FE Q36052963-FC12591A-4233-45C2-83AA-8EA4EA7D45DD Q36103098-6522106B-0D13-4EF7-BD59-28BFF4EF8E26 Q36133794-4D38B468-19B1-4E62-BC36-BD04BDADBF4B Q36334385-02838924-A6D7-4619-95A4-369DDF273AC6 Q36741778-979FBF8A-3B16-42D1-8EEC-74E55DD9A772 Q36848958-24800E3D-B854-4BDD-B3E8-F7E70BE33CA5 Q36924982-99154F47-DB4D-41FA-BF22-2676808853A8 Q36953735-738FE49E-F0D6-4803-AE7B-4D0AB9C76CB2 Q37189531-123E643C-E529-45DE-9EBD-E34CCD3439AA Q37246465-DBBE5C81-87F8-4724-AF9F-9C74F43DB05D Q37288731-4CBD1D96-F513-4F28-B2BB-9687CF6BAEC7 Q37608313-713F52B5-1E8A-4424-B1F0-B4998D3C809F Q37625268-2AE097BA-57AC-4AB3-943D-5A1D7DEC2511 Q38198618-02D9A57B-73C7-468E-BECB-8D9B4829C16C Q38232812-7263E93B-BAA7-4337-B5F0-219104E9661C Q38314738-37144DEA-8F39-4355-B1C8-826CBFF124D3 Q38397998-43E8219A-D236-43CF-BAAA-0288A58DB5D5

P2860

A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.

http://www.wikidata.org/entity/Q39430232

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@en

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@nl

type

label

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@en

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@nl

prefLabel

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@en

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@nl

P1433

Q39430232-1EC764EB-55EB-4ED7-8D09-44B356D9ED61

P1476

Q39430232-34F6B7F0-3D1B-43D0-9EC2-9031239AE424

P2093

Q39430232-0426422B-44C5-4812-84DD-A33F5CAB5B86

Q39430232-12A33A46-50F0-4E9E-B180-2555B2C1E76B

Q39430232-1BD7628D-3A73-4AE7-953D-4D621056FE11

Q39430232-2170B4FD-16F3-4C44-9E77-F295B7B99FBB

Q39430232-4BE728E4-CAB9-4C37-AD0B-DDA847785FF4

Q39430232-69314B44-8D37-4D1B-98AE-D4C4CBA53370

Q39430232-B05DC257-D718-42DE-82CA-B5C46426D1F5

Q39430232-C01ADD82-AE15-4DFB-A2AF-A56D1EDAC576

Q39430232-C480C9EB-2F08-466C-8060-C6D2D4B994A2

Q39430232-D3F5DF82-96DF-4518-A747-954DB71FE290

P304

Q39430232-4263A078-30B4-4BBB-AF38-1BBFF145C7F2

P31

Q39430232-CE1667C6-8912-4C03-B777-5110C1A34AA7

P356

Q39430232-29A8326E-F241-4D23-B964-97D5081852F6

P407

Q39430232-1C63CD54-F0A2-4A47-BB56-88F5C6E5194B

P433

Q39430232-6E8C3824-B865-4977-A01D-B9B4BBC6E00B

P478

Q39430232-8A938447-232A-4F3A-A811-5BE07A3C4A44

P50

Q39430232-42068579-B9F1-493C-B87C-E4D558FF8967

Q39430232-ED4D935C-CEA8-4A6B-A793-0338C1C41310

P577

Q39430232-8E71C4F4-48E8-49A4-8902-B09ABB5A6D5C

P5875

Q39430232-C43F8290-92BC-424D-8C1D-61CE9447AE38

P698

Q39430232-B94EEF68-03A3-4D79-A358-FA875BB1922B

P921

Q39430232-2AC8BB65-D8BE-451E-889F-7DC27EF1764C

Q39430232-6DC400C0-9284-46B3-AD38-FD7A41C24FE8

Q39430232-82EAC9D9-AE1E-4BB1-93B9-0F60CE24E0B9

P356

P1433

Clinical Infectious Diseases

P1476

A risk for hepatocellular carc ...... C-associated liver cirrhosis.

@en

P2093

Fredrik Granath

http://www.w3.org/2001/XMLSchema#string

Hans Norrgren

http://www.w3.org/2001/XMLSchema#string

Hans Verbaan

http://www.w3.org/2001/XMLSchema#string

Loa Davidsdottir

http://www.w3.org/2001/XMLSchema#string

Magnus Hedenstierna

http://www.w3.org/2001/XMLSchema#string

Nina Rose

http://www.w3.org/2001/XMLSchema#string

Nogol Rahbin

http://www.w3.org/2001/XMLSchema#string

Per Stål

http://www.w3.org/2001/XMLSchema#string

Rolf Hultcrantz

http://www.w3.org/2001/XMLSchema#string

Soo Aleman

http://www.w3.org/2001/XMLSchema#string

P304

230-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT234

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236328900

http://www.w3.org/2001/XMLSchema#string

P698

23616492

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis